Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lipid envelope is a host-derived membrane that encapsulates the viral genome and nucleocapsid, playing a vital role in the virus's life cycle (Source: Nature Reviews Microbiology, 2020). It is primarily composed of phospholipids and cholesterol acquired from the host's endoplasmic reticulum-Golgi intermediate compartment during the budding process (Source: Journal of Biological Chemistry, 2021). This envelope acts as a structural scaffold for the Spike (S), Membrane (M), and Envelope (E) proteins, which are essential for host cell recognition and entry (Source: Cell, 2020). Because the integrity of this lipid bilayer is required for the virus to fuse with host cell membranes, it represents a critical vulnerability for inactivation (Source: Lancet Microbe, 2020). Disruption of the envelope by surfactants, detergents, or organic solvents like ethanol leads to the immediate loss of viral infectivity (Source: CDC, 2022). Consequently, the lipid envelope is the primary target for most environmental disinfectants and antiseptic mouthwashes or nasal sprays designed to reduce viral transmission (Source: Journal of Hospital Infection, 2020). While it is a robust target for external inactivation, the lack of specificity compared to viral proteins poses significant challenges for developing systemic therapeutic agents (Source: Trends in Pharmacological Sciences, 2021). Research continues into lipid-modulating compounds that might interfere with the envelope's formation or stability during the viral replication cycle (Source: Frontiers in Microbiology, 2021).
The primary mechanism involves the solubilization and disruption of the lipid bilayer by amphiphilic molecules or organic solvents, which leads to the denaturation of embedded proteins and the loss of the virus's ability to fuse with host cell membranes (Source: Journal of Hospital Infection, 2020; CDC, 2022).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lipid envelope (SARS-CoV-2 lipid envelope).